Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
List view / Grid view
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Scientists developed a new culture technique for alveolospheres which they used to study how alveolar cells respond to SARS-CoV-2 infection.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
The non-human primate model exhibited a COVID-19-like disease and showed how symptoms and viral activity change over the course of SARS-CoV-2 infection.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.